Increasing Demand For Personalized Medicine Driving The Market Due To Advances In Genomics And Tailored Treatment Approaches: The Driving Engine Behind Small Molecule Targeted Therapy Market Evolution in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Small Molecule Targeted Therapy Market Size Growth Forecast: What to Expect by 2025?
The market for small molecule targeted therapy has been on a robust growth trajectory in the recent years. The market size is projected to escalate from $70.45 billion in 2024 to $77.29 billion in 2025, with a compound annual growth rate (CAGR) of 9.7%. The substantial growth during the historic period can be credited to factors such as the proliferation of advanced diagnostic tools, a surge in the amount of clinical trials, an increased focus on the treatment of oncology and rare diseases, an uptick in regulatory approvals for innovative small molecule medicines, as well as a growing emphasis on combination therapies.

How Will the Small Molecule Targeted Therapy Market Size Evolve and Grow by 2029?
Over the coming years, the small molecule targeted therapy market is projected to witness robust growth. It is anticipated to reach $110.52 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 9.4%. This growth during the predicted period can be linked to various factors such as the growing instances of chronic and genetic diseases, the surging acceptance of personalized medicine, increasing investments in pharmaceutical R&D, heightened awareness amongst healthcare professionals and patients alike, and escalating governmental support and funding. Significant trends for the forecast period incorporate advancements in drug design technology, progress in high-throughput screening methods, precision medicine platform developments, technology-fuelled enhancements in drug delivery systems, and the merging of genomics and proteomics data.

View the full report here:
https://www.thebusinessresearchcompany.com/report/small-molecule-targeted-therapy-global-market-report

What Drivers Are Propelling the Growth of Small Molecule Targeted Therapy Market Forward?
The increased focus on personalized medicine is projected to drive the expansion of the small molecule targeted therapy market. Personalized medicine is a healthcare strategy that customizes prevention, diagnosis, and treatment based on a person's genetic make-up, environmental influences, and lifestyle habits. The surge in personalized medicine is propelled by advancements in genomics, facilitating a more in-depth comprehension of unique genetic alterations and permitting more accurate, targeted treatments that optimize patient results and minimize guesswork in therapies. Small molecule targeted therapy promotes personalized medicine by distinctly targeting a patient's specific molecular or genetic disease characteristics, enhancing treatment efficiency and minimizing side effects. For example, the Personalized Medicine Coalition, a non-profit organization based in the US, reported in February 2024 that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from six in 2022. The recently sanctioned personalized treatments for 2023 incorporated seven cancer drugs and three for additional diseases and conditions. Consequently, the escalating importance placed on personalized medicine is fuelling the enlargement of the small molecule targeted therapy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28332&type=smp

Which Emerging Trends Are Transforming the Small Molecule Targeted Therapy Market in 2025?
Major corporations involved in the small molecule targeted therapy market are concentrating on crafting cutting-edge solutions like oral small molecules. This innovation aims to optimize targeted delivery, increase patient adherence, and concentrate on specific molecular pathways in cancer and other chronic ailments. Oral small molecules, light molecular weight medications that can be consumed orally, are contrived to easily infiltrate cells and specifically target disease-related proteins or pathways. For example, in June 2025, Kura Oncology Inc., a biotech firm based in the U.S., obtained FDA approval for a New Drug Application (NDA) for ziftomenib, intended for adults with relapsed or refractory acute myeloid leukemia (AML) having nucleophosmin 1 (NPM1) mutations. As an oral targeted therapy, ziftomenib is specifically meant for adult patients with relapsed or refractory AML featuring NPM1 mutations, filling a substantial unaddressed medical necessity. With a favorable safety profile, ziftomenib has shown encouraging effectiveness, as indicated by significant complete remission rates in clinical trials. Its selective inhibition of the menin-KMT2A interaction interferes with leukemic cell growth, bolstering new treatment alternatives for this difficult-to-manage AML subtype.

What Are the Key Segments in the Small Molecule Targeted Therapy Market?
The small molecule targeted therapy market covered in this report is segmented as

1) By Type Of Therapy: Chemotherapy, Targeted Therapy, Immunotherapy
2) By Drug Class: Monoclonal Antibodies, Small Molecule Inhibitors, Combination Therapies
3) By Mechanism Of Action: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (Ahr) Modulators, Cell Cycle Inhibitors
4) By Disease Indication: Cancer, Autoimmune Diseases, Infectious Diseases
5) By Route Of Administration: Oral, Intravenous, Subcutaneous

Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-microtubule Agents
2) By Targeted Therapy: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (AhR) Modulators
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28332&type=smp

Who Are the Key Players Shaping the Small Molecule Targeted Therapy Market's Competitive Landscape?
Major companies operating in the small molecule targeted therapy market are F. Hoffmann-La Roche AG (Roche), Merck KGaA, Pfizer Inc., Bayer AG, Sanofi S.A., Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, Blueprint Medicines Corporation, Kura Oncology Inc., G1 Therapeutics Inc., Ascentage Pharma Group International Inc., Rgenta Therapeutics Inc., Verastem Inc.

What Geographic Markets Are Powering Growth in the Small Molecule Targeted Therapy Market?
North America was the largest region in the small molecule targeted therapy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in small molecule targeted therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28332

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.